Exclusive NASDAQ MarketSite Interview with Aethlon Medical, Inc. CEO James Joyce

NEW YORK, April 5, 2016 /PRNewswire/ —, a leader in the financial media and news space, today announces an exclusive HD video interview with Aethlon Medical, Inc. (NASDAQ:AEMD) Chairman & CEO James Joyce from the floor of the NASDAQ MarketSite.Mr. Joyce shares with us his vision for the Company and why he believes 2016 will be an essential year for Aethlon.

The interview provides unique insights into the Company’s latest corporate developments and catalysts, as well as an update on recently achieved milestones. Additionally, Mr. Joyce provides his perspective on how Aethlon distinguishes itself from other medical device companies.

Year to date, shares of Aethlon Medical, Inc. (NASDAQ:AEMD) reached a 52 week low of $4.02 (based on February 9th, 2016 ) and have since rebounded up roughly 45% to $5.89 (Market Price close as of April 4th, 2016).

Watch the full HD Video Interview now and see why interest continues to grow for Aethlon Medical, Inc. (NASDAQ:AEMD).

Click here to view full HD quality video interview

About Financial Buzz Media, a leading informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content.

Financial Buzz Media provides credible financial news branding, marketing and advertising through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, TV Broadcasting, and Financial Publications. In a public financial market that requires extensive transparency, Financial Buzz Media provides one of the most internationally credible media outlets by reporting live from various locations; The New York Stock Exchange, NASDAQ Exchange and Hong Kong Exchange.

For “the latest buzz in financial news” every day, please visit

About Aethlon Medical, Inc. 

Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. The Aethlon Hemopurifier® is a leading broad-spectrum treatment countermeasure against infectious viral pathogens. The device, which has been successfully administered to individuals infected with HIV, Hepatitis C (HCV) and Ebola virus, is currently the subject of FDA approved clinical studies. Aethlon is also studying the potential use of the Hemopurifier® to address exosomes secreted by tumors to promote the spread of metastasis and suppress the immune system of cancer patients. The Company provides government contracting services to the Defense Advanced Research Projects Agency (DARPA) related to the development of a biofiltration device to treat sepsis and maintains majority ownership of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor Chronic Traumatic Encephalopathy (CTE) and other neurological disorders. Additional information can be found online at

Media Contact: 

Danny Abramov +1(877)-601-1879 or

Leave a Comment